0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Hepatitis Temporally Associated With an Herbal Supplement Containing Artemisinin—Washington, 2008 FREE

JAMA. 2009;302(13):1412-1414. doi:.
Text Size: A A A
Published online

MMWR. 2009;58:854-856

Artemisinins are a class of compounds that include artesunate, artemether, and artemisinin and have potent antimalarial activity. In combination with other drugs (artemisinin combination therapy), these compounds are the first-line treatment recommended by the World Health Organization for Plasmodium falciparum infections. Artemisinins have been available in the United States without a prescription as herbal supplements for at least 10 years; these supplements are marketed for general health maintenance and for treatment of parasitic infections and cancers. On August 27, 2008, CDC was notified of a patient who developed hepatitis after a 1-week course of an herbal supplement containing artemisinin. The patient had abdominal pain, dark urine, and laboratory results consistent with hepatitis (e.g., serum alanine aminotransferase of 898 IU/L [normal: 10-55 IU/L]). Samples of the supplement were sent to CDC and the Georgia Institute of Technology for analysis to determine the amount of artemisinin and to identify any contaminants. Analysis indicated that the supplement contained 94%-97% of the 100 mg of artemisinin stated on the packaging and the supplement contained no other common pharmaceutical active ingredients. Given the patient's clinical course and laboratory evaluation, CDC investigators concluded that the hepatitis might have been associated with ingestion of the herbal supplement containing artemisinin. More data are needed to establish any causal connection between artemisinin and hepatitis. Health-care providers should be aware of the possibility of hepatic toxicity in patients taking herbal supplements containing artemisinin.

CASE REPORT

On August 21, 2008, a man aged 52 years in Seattle, Washington, went to his primary-care physician with symptoms of severe fatigue and dark urine. His medical history included lactose intolerance and irritable bowel syndrome but no known hepatic dysfunction or alcohol abuse. His only medication was a multivitamin. Two weeks earlier, the patient had visited a naturopathic provider for long-standing abdominal discomfort that the provider attributed to a parasitic infection after stool studies reportedly showed an “unidentifiable protozoan.” The naturopathic provider had started him on a 6-week course of an herbal supplement containing 100 mg of artemisinin, two capsules orally three times a day, resulting in a dose of 7.5 mg/kg/day of artemisinin. The supplement was manufactured and sold through a company in the United States. Approximately 1 week into therapy, the patient developed worsening abdominal pain and dark urine. Three days later, on August 18, he stopped taking the supplement when his symptoms did not abate, and 3 days after that, he went to his primary-care physician.

Physical examination by the primary-care physician revealed mild scleral icterus and upper abdominal tenderness. The patient reported no fever, cough, diarrhea, or other symptoms. He reported no significant alcohol use, additional use of over-the-counter medications (e.g., acetaminophen), ill contacts, recent international travel, or exposure to unsafe food or water. Laboratory findings were consistent with hepatitis: a serum alanine aminotransferase of 898 IU/L (normal: 10-55 IU/L), aspartate aminotransferase of 280 IU/L (normal: 10-40 IU/L), bilirubin of 3.1 mg/dL (normal: 0.2-1.2 mg/dL), and alkaline phosphatase of 258 IU/L (normal: 40-150 IU/L). Five months earlier, on March 12, as part of an evaluation for inflammatory bowel disease, all laboratory values had been found within normal ranges.

Among laboratory findings on August 21, the following were within normal ranges: white blood cell count, hemoglobin, hematocrit, platelets, sodium chloride, serum creatinine, glucose, and calcium. The patient's potassium (3.4 mmol/L [normal: 3.4-5.2 mmol/L]) and carbon dioxide content (22 mmol/L [normal: 22-31 mmol/L]) were borderline normal, and blood urea nitrogen was just below the normal range (8 mg/dL [normal: 9-25 mg/dL]). Laboratory analysis for hepatitis A antibody total and antibody IgM; hepatitis B core antibody, core antibody IgM, surface antigen, and surface antibody; and hepatitis C antibody all were negative. Laboratory testing detected no acetaminophen. Examination of the patient's stool for ova and parasites was negative.

The patient was admitted to the hospital on August 21, for continued monitoring and supportive care and discharged home on hospital day 3. During the next 2 weeks, the patient's liver function test results and symptoms gradually improved and had returned to normal by September 4.

HERBAL SUPPLEMENT ANALYSIS

On September 8, two samples from the patient's home supply of the herbal supplement were sent to CDC for analysis with high-performance liquid chromatography to determine whether the supplement contained 100 mg of artemisinin as stated on the packaging. Additional samples from the same bottle were sent to the Georgia Institute of Technology to identify any other clinically relevant organic contaminants by mass spectrometry. The CDC analysis indicated 94 mg and 97 mg of artemisinin in the supplement; no contaminants or additional organic active pharmaceutical ingredients were found in the other samples.

REPORTED BY:

U Malhotra, MD, R Rakita, MD, Infectious Diseases Section, Virginia Mason Medical Center, Seattle, Washington. F Fernandez, PhD, G Harris, School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia. P Arguin, MD, R Bronzan, MD, L Slutsker, MD, M Green, PhD, Div of Parasitic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases; D Townes, MD, EIS Officer, CDC.

CDC EDITORIAL NOTE:

Artemisinin (called qinghaosu in Chinese) is found in the leaves of Artemisia annua (the sweet wormwood shrub) and has long been used as an herbal treatment in China. Although widely used in herbal supplements of U.S. manufacturers, until recently artemisinins were not available for medical use in the United States except from CDC under an investigational new drug protocol.1 In April 2009, an artemisinin combination therapy, artemether-lumefantnrine (Coartem [Novartis]), was approved by the Food and Drug Administration (FDA) for the treatment of malaria.* Artemisinin-containing therapies generally are considered safe, effective, and well-tolerated medications for the treatment of malaria caused by P. falciparum with no major side effects.24 Although hepatic toxicity in humans has been reported from ingestion of a wide range of herbal preparations, a search of the literature revealed no previously published reports of hepatic toxicity from an herbal supplement containing artemisinin. However, FDA's Center for Food Safety and Applied Nutrition has additional reports of adverse events involving ingestion of artemisinin-containing dietary supplement products that were not included in this review (FDA, unpublished data, 2009).

In the case described in this report, the patient's presentation, history, and clinical course suggest that his hepatitis might have resulted from ingestion of an artemisinin-containing herbal supplement over a 10-day period. An investigation did not identify any other etiology for the hepatitis, and after the patient stopped taking the herbal supplement (7.5 mg/kg/day), a gradual but complete resolution of the patient's signs and symptoms resulted. However, further study is needed to delineate any causal connection between artemisinin and hepatitis.

In a review of 108 trials of artemisinins involving 9,241 patients, only 0.9% had isolated elevated aspartate aminotransferase associated with artemisinin derivatives.3,5 Elevated liver enzymes have been observed in patients treated for malaria with artemisinins but are generally thought to have resulted from the underlying malaria rather than the artemisinins. In other countries, the commonly recommended oral therapeutic dose of artesunate is 4 mg/ kg/day for 3 days when used in combination with other drugs for treatment of acute malaria. Because the chemical structures of the artemisinins (i.e., artesunate, artemether, and artemisinin) are similar and they are metabolized into the same active compound in the body (dihydroartemisinin), the therapeutic windows for these compounds are similar. Therefore, the 10-day regimen of artemisinin herbal supplement at 7.5mg/kg/day described in this report is substantially more than the dosage of artesunate routinely used for treatment of malaria.

In laboratory testing, rats given 600 mg/kg/day of artemisinin for 7 days demonstrated slight degenerative changes in the liver, heart, spleen, lung, and kidney, and dogs given 100 mg/kg/day of artemisinin for 7 days had minimal observable physiologic effects.6 The only reports of hepatic toxicity caused by artemisinin compounds in laboratory animals were in guinea pigs exposed to 16 mg/kg/day of artesunate for 7 days and in rats exposed to 4 mg/kg/day of artesunate for 5 days.7,8 However, limitations exist in comparing animal ingestions of artesunate with human ingestion of artemisinin, although they are closely related compounds.

FDA regulates herbal supplements under a different standard than food, over-the-counter medications, and prescription medications. Under the Dietary Supplement Health and Education Act of 1994, the manufacturer is responsible for ensuring the safety of a dietary supplement, and FDA takes action against unsafe supplements after they reach the market. Because federal regulation of dietary supplements differs from that for pharmaceuticals, potential concerns arise about quality control, recommended indications, and unsupervised usage. Herbal supplements also can potentially interact with other medications and reduce or potentiate their effects, which can include toxicity.9 Health-care providers should be aware that patients might be taking herbal supplements containing artemisinin and consider inquiring about their use in patients being evaluated for hepatitis without a clear etiology. Adverse events or illnesses thought related to the use of artemisinin-containing dietary supplements should be reported to FDA by telephone (1-800-FDA-1088) or via the Internet (http://www.fda.gov/safety/medwatch/howtoreport/ucm053074.htmonline). Additional information is available at http://www.fda.gov/food/dietarysupplements/alerts/ucm111110.htm.

REFERENCES

CDC.  New medication for severe malaria available under an investigational new drug protocol.  MMWR. 2007;56:769-770
Price R, Van Vugt M, Phaipun L,  et al.  Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.  Am J Trop Med Hyg. 1999;60(4):547-555
PubMed
Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate.  Clin Infect Dis. 2008;47(6):804-811
PubMed   |  Link to Article
Taylor WR, White NJ. Antimalarial drug toxicity: a review.  Drug Saf. 2004;27(1):25-61
PubMed   |  Link to Article
Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials.  Med Trop. 1998;58(3):(suppl)  50-53
China Cooperative Research Group.  Studies on the toxicity of qinghaosu and its derivatives.  J Tradit Chin Med. 1982;2(1):31-38
PubMed
Nwanjo HU, Oze G. Acute hepatotoxicity following administration of artesunate in guinea pigs.  Internet J Toxicol. 2007;4(1):
Omotuyi IO, Nwangwu SC, Okugbo OT, Okoye OT, Ojieh GC, Wogu DM. Hepatotoxic and hemolytic effects of acute exposure of rats to artesunate overdose.  Afr J Biochem Res. 2008;2:107-110
Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions.  Curr Drug Metab. 2008;9(10):1027-1037
PubMed   |  Link to Article

Figures

Tables

References

CDC.  New medication for severe malaria available under an investigational new drug protocol.  MMWR. 2007;56:769-770
Price R, Van Vugt M, Phaipun L,  et al.  Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives.  Am J Trop Med Hyg. 1999;60(4):547-555
PubMed
Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate.  Clin Infect Dis. 2008;47(6):804-811
PubMed   |  Link to Article
Taylor WR, White NJ. Antimalarial drug toxicity: a review.  Drug Saf. 2004;27(1):25-61
PubMed   |  Link to Article
Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials.  Med Trop. 1998;58(3):(suppl)  50-53
China Cooperative Research Group.  Studies on the toxicity of qinghaosu and its derivatives.  J Tradit Chin Med. 1982;2(1):31-38
PubMed
Nwanjo HU, Oze G. Acute hepatotoxicity following administration of artesunate in guinea pigs.  Internet J Toxicol. 2007;4(1):
Omotuyi IO, Nwangwu SC, Okugbo OT, Okoye OT, Ojieh GC, Wogu DM. Hepatotoxic and hemolytic effects of acute exposure of rats to artesunate overdose.  Afr J Biochem Res. 2008;2:107-110
Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions.  Curr Drug Metab. 2008;9(10):1027-1037
PubMed   |  Link to Article

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles